Clinical Studies
MERLOT
This postmarketing study will begin in the United Kingdom in Q1 2009. It is a head-to-head comparison of NeoVista epimacular beta radiation therapy and standard-of-care treatment with Lucentis.
This postmarketing study will begin in the United Kingdom in Q1 2009. It is a head-to-head comparison of NeoVista epimacular beta radiation therapy and standard-of-care treatment with Lucentis.